Better Therapeutics, Inc. is a prescription digital therapeutics (PDT) company, which is engaged in developing a software-based novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases (CMDx). Its platform allows for the creation of multiple PDTs that are designed to treat patients with CBT, delivered digitally via an app, to address the underlying causes of CMDx. Its lead PDT product candidate, AspyreRx, is a digital behavioral therapeutic delivering CBT for the treatment of a cardiometabolic disease. AspyreRx is a prescription-only digital treatment indicated to provide cognitive behavioral therapy to patients 18 years or older with T2D. The device targets behavior to aid in the treatment of T2D. Its pipeline also includes programs for the treatment of hypertension, hyperlipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH) and chronic kidney disease.

Employees

Sector

Biotechnology & Medical Research

More about the company

Real-time OTC Markets 09:36:46 2026-05-29 EDT			5-day change	1st Jan Change
0.000100 ^USD	-.--%		-.--%	-

24-05-21	Click Therapeutics, Inc. acquired Assets of Better Therapeutics, Inc..	CI
24-03-21	Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc	CI

Market Cap	9.24M 8.24M 7.63M 6.94M 13.02M 876M 13.24M 91.55M 36M 458M 34.68M 33.96M 1.46B	P/E 2021	-1.5x	P/E 2022	-0.65x
Enterprise Value	8.38M 7.47M 6.92M 6.29M 11.81M 795M 12.01M 83.03M 32.65M 415M 31.45M 30.8M 1.33B	EV / Sales 2021	-	EV / Sales 2022	-
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

24-05-21	Click Therapeutics, Inc. acquired Assets of Better Therapeutics, Inc..	CI
24-03-21	Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc	CI
24-03-19	Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from S&P TMI Index	CI
24-03-14	Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from NASDAQ Composite Index	CI
24-03-14	Better Therapeutics to Terminate Employees, Explore Strategic Alternatives; Shares Drop Sharply	MT
24-03-14	BETTER THERAPEUTICS SHARES DOWN 80% AFTER CO SAYS IT WILL EXPLOR…	RE
24-02-20	Better Therapeutics' Platform Targeting Advanced Liver Disease Receives FDA Breakthrough Device Designation	MT
24-02-20	Better Therapeutics Gets Breakthrough Device Designation For Cognitive Behavioral Therapy Platform	DJ
24-02-20	Better Therapeutics, Inc. Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease	CI
24-01-22	Better Therapeutics, Inc. announced that it has received $0.25 million in funding	CI
24-01-17	Better Therapeutics Inc. Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx Is More Effective and Less Costly Than Standard of Care Alone	CI
24-01-04	Better Therapeutics, Inc. announced that it expects to receive $0.25 million in funding	CI
24-01-03	Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States	CI

23-04-14	Lake Street Adjusts Better Therapeutics' Price Target to $5 From $6, Keeps Buy Rating	MT
23-03-31	Chardan Lowers Price Target on Better Therapeutics to $9 From $14, Reflecting Higher Projected Sharecount Dilution, Maintains Buy Rating	MT
22-11-15	Chardan Cuts Price Target on Better Therapeutics to $14 From $17 on Higher Expected Share Count Dilution, Reiterates Buy Rating	MT
22-07-29	Chardan Adjusts Better Therapeutics' Price Target to $17 From $15, Keeps Buy Rating	MT
22-03-16	Chardan Raises Price Target on Better Therapeutics to $18 From $17, Maintains Buy Rating	MT

Better Therapeutics, Inc. Stock

Stocks

BTTX

US08773T1043

Biotechnology & Medical Research

Valuation: Better Therapeutics, Inc.

Chart: Better Therapeutics, Inc.

Latest news: Better Therapeutics, Inc.

Analysts' recommendations: Better Therapeutics, Inc.

Press Releases: Better Therapeutics, Inc.

News in other languages: Better Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Better Therapeutics, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

24-05-23	Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.	AQ
24-03-14	Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq	BU
24-03-14	Better Therapeutics : Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq - Form 8-K	PU
24-03-05	Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers	BU
24-03-04	Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)	BU

23-07-11	MÄRKTE USA/Wall Street setzt auf niedrige Inflation
23-07-11	Aktien New York: China-Konjunkturmassnahmen stützen den Dow
23-07-11	MÄRKTE USA/Wall Street vor Inflationsdaten positiv gestimmt
23-07-11	Aktien New York Ausblick: Freundlich erwartet dank China-Konjunkturmassnahmen

1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0.27
5 years	0		29.4
10 years	0		29.4

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/9/24	David Perry	Free	Founder	839,895	1.6844%
1/9/24	David Perry	Free	Founder	1,471,453	2.9511%
12/18/23	Andrew Armanino	Free	Director	3,750	0.0079%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BETTER THERAPEUTICS, INC.	-.--%	-.--%	-.--%	-99.95%	5.45K
WUXI APPTEC CO., LTD.	+1.52%	-7.16%	+51.66%	+67.41%	65B
LONZA GROUP AG	+1.52%	+6.83%	+10.89%	+79.30%	51.2B
ARGENX SE	+0.30%	-0.46%	-0.03%	+61.89%	51.19B
IQVIA HOLDINGS INC.	-0.80%	+0.95%	+24.82%	+41.73%	43.93B
BEONE MEDICINES AG	+0.39%	+5.73%	+16.29%	+133.49%	41.96B
REVOLUTION MEDICINES, INC.	+2.48%	-6.30%	+236.47%	+526.66%	38.14B
CELLTRION, INC.	+2.16%	+10.36%	+18.92%	+59.70%	33.24B
WUXI BIOLOGICS (CAYMAN) INC.	-0.90%	-10.49%	+37.09%	+1.80%	25.2B
GENMAB A/S	+1.60%	+2.21%	+27.96%	+28.00%	22.5B
Average	+0.79%	+0.13%	+42.41%	+90.00%	37.24B
Weighted average by Cap.	+0.90%	+0.04%	+45.39%	+112.24%

	2021	2022
Net sales	-	-
Net income	-40.34M -35.95M -33.31M -30.28M -56.83M -3.82B -57.76M -399M -157M -2B -151M -148M -6.39B	-39.76M -35.44M -32.83M -29.85M -56.02M -3.77B -56.94M -394M -155M -1.97B -149M -146M -6.3B
Net Debt	-31.06M -27.69M -25.65M -23.32M -43.76M -2.94B -44.48M -308M -121M -1.54B -117M -114M -4.92B	-860K -767K -710K -646K -1.21M -81.54M -1.23M -8.52M -3.35M -42.62M -3.23M -3.16M -136M